Drug intelligence / Profile preview

M2RLAB 001

Development stage: Phase 2
Lead developer: XCELL Medical Solutions
Modality: Cell Therapies
Administration: Intravenous

Overview

M2RLAB 001 is an autologous cell therapy developed by M2R Lab for the treatment of acute kidney injury (AKI), particularly in patients undergoing cardiac surgery. The therapy consists of the patient's own leukocytes that have been isolated and modified using M2R's proprietary technology to adopt an anti-inflammatory and pro-regenerative phenotype. By reintroducing these modified cells into the patient, the treatment aims to modulate the immune response at the site of injury, reduce inflammation, and accelerate the recovery of renal function. M2RLAB 001 is currently being evaluated in clinical trials to assess its safety and efficacy in reducing the time to kidney function recovery post-surgery.

Other names: Modified Autologous Leukocyte Cells

Beyond the preview

Go deeper on M2RLAB 001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on M2RLAB 001.

Explore the full profile